Catalyst

Slingshot members are tracking this event:

Vertex (VRTX) Announces Phase 3 Results Evaluating ORKAMBI in Children 6-11 with Cystic Fibrosis with Two Copies of F508del Mutation

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
VRTX

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 07, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Results, Orkambi, Children, 6-11, Cystic Fibrosis, F508del Mutation, Two Copies